drugset / Trial / NCT00829374

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374

Phase 3 Completed 1003 enrolled Medivation, Inc. Pfizer · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.

Timeline

Start
2009-03
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Latrepirdine Small molecule 5 mg Oral
Subject Latrepirdine Small molecule 20 mg Oral

Indications